Rockefeller Capital Management
ANIP icon

Rockefeller Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Rockefeller Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.38K Sell
65
-48
-42% -$3.85K ﹤0.01% 4217
2026
Q1 		$8.69K Sell
113
-63
-36% -$4.92K ﹤0.01% 4058
2025
Q4 		$13.9K Buy
176
+126
+252% +$10.9K ﹤0.01% 3667
2025
Q3 		$4.58K Buy
+50
New +$4.08K ﹤0.01% 3892
2023
Q1 		– Sell
-6
Closed – – 2063
2022
Q4 		$0 Hold
6
– – ﹤0.01% 3833
2022
Q3 		$0 Sell
6
-38
-86% -$1.3K ﹤0.01% 3863
2022
Q2 		$1K Buy
+44
New +$1.27K ﹤0.01% 3898
2019
Q2 		– Sell
-99
Closed -$7K – 1648
2019
Q1 		$7K Hold
99
– – ﹤0.01% 1553
2018
Q4 		$4K Hold
99
– – ﹤0.01% 814
2018
Q3 		$6K Hold
99
– – ﹤0.01% 650
2018
Q2 		$7K Buy
+99
New +$6.18K ﹤0.01% 657

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's ANIP Position: Q2 2026 in Review

Rockefeller Capital Management reduced its ANI Pharmaceuticals (ANIP) stake by 42% in Q2 2026, selling an estimated $3.85K and leaving 65 shares worth $5.38K. The position accounts for ﹤0.01% of the portfolio, ranked #4217.

Rockefeller Capital Management first reported a position in ANIP in Q2 2018 and has held it in 11 quarters since. The position peaked at $13.9K in Q4 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Rockefeller Capital Management held 65 shares of ANI Pharmaceuticals worth $5.38K as of Q2 2026.
  • Rockefeller Capital Management sold 48 ANI Pharmaceuticals shares in Q2 2026, an estimated $3.85K.
  • ANI Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4217 holding.
  • Rockefeller Capital Management first reported a position in ANI Pharmaceuticals in Q2 2018 and has held it in 11 quarters since.
  • Rockefeller Capital Management's ANI Pharmaceuticals position peaked at $13.9K in Q4 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.